We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Indivior plc (INDV) ORD USD0.5

Sell:1,537.00p Buy:1,540.00p 0 Change: 13.00p (0.85%)
FTSE 250:0.02%
Market closed Prices as at close on 17 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 13.00p (0.85%)
Market closed Prices as at close on 17 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 13.00p (0.85%)
Market closed Prices as at close on 17 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.

Contact details

234 Bath Road
United Kingdom
+ (0) 8043791090

Important dates

Future events
AGM 09 May 2024 09/05/24
Quarterly results 25 April 2024 25/04/24
Past events
Annual report 13 March 2024 13/03/24
Annual report 07 March 2024 07/03/24
Final results 22 February 2024 22/02/24
Quarter 4 results 22 February 2024 22/02/24
Quarter 3 results 09 November 2023 09/11/23
Quarter 2 results 27 July 2023 27/07/23
Interim results 27 July 2023 27/07/23
AGM 04 May 2023 04/05/23
Quarterly results 27 April 2023 27/04/23

General stock information

Market cap:
£2.10 billion
Shares in issue:
135.68 million
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence
FTSE 250,FTSE 350,FTSE All Share

Key personnel

  • Mark Crossley
    Chief Executive Officer, Executive Director
  • Ryan Preblick
    Chief Financial Officer, Executive Director
  • Jon Fogle
    Chief Human Resource Officer
  • Christian Heidbreder
    Chief Scientific Officer
  • Cynthia Cetani
    Chief Integrity and Compliance Officer
  • Jeffrey Burris
    Chief Legal Officer
  • Vishal Kalia
    Chief Impact and Strategy Officer
  • Richard Simkin
    Chief Commercial Officer
  • Hillel West
    Chief Manufacturing and Supply Officer
  • Kathryn Hudson
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.